
Check-Cap Ltd. CHEK
Annual report 2024
added 03-07-2026
Check-Cap Ltd. Total Assets 2011-2026 | CHEK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Check-Cap Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 377 K | 25 M | 45.4 M | 55.7 M | 19.6 M | 9.43 M | 15.4 M | 7.91 M | 12.3 M | 15.3 M | 7.78 M | 5.38 M | 8.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 377 K | 17.6 M |
Quarterly Total Assets Check-Cap Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 55.7 M | - | 32.6 M | - | 19.6 M | - | 17.9 M | - | 9.43 M | - | 15.9 M | - | 15.4 M | - | 20.8 M | - | 7.91 M | - | 10.1 M | - | 12.3 M | - | 10.7 M | - | 15.3 M | - | - | - | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 55.7 M | 2.98 M | 17.6 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
94.3 M | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
684 M | $ 8.62 | 0.23 % | $ 574 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Castle Biosciences
CSTL
|
531 M | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
413 M | $ 17.01 | 3.4 % | $ 906 M | ||
|
DexCom
DXCM
|
6.34 B | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 14.77 | 0.61 % | $ 447 M | ||
|
Guardant Health
GH
|
2.01 B | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
97.2 M | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
16.1 M | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Danaher Corporation
DHR
|
83.5 B | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
29.9 B | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
6.3 B | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
10.7 B | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
76.7 M | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 9.0 | -0.99 % | $ 255 M | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 450.41 | 1.48 % | $ 13 B | ||
|
National Research Corporation
NRC
|
135 M | $ 16.52 | 0.12 % | $ 370 M | ||
|
Celcuity
CELC
|
245 M | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | ||
|
NeoGenomics
NEO
|
1.36 B | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
OPKO Health
OPK
|
2.2 B | $ 1.19 | 2.59 % | $ 826 M | ||
|
Natera
NTRA
|
1.39 B | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.66 | -3.92 % | $ 432 M | ||
|
Pacific Biosciences of California
PACB
|
784 M | $ 1.33 | 4.72 % | $ 399 M |